Bromoxol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromoxol

Here is a structured overview of Bromoxol, detailing its identity, composition, and general purpose.

Property Description
Active ingredient Bromhexine Hydrochloride
Form Syrup, Oral Solution, Tablets
Pharmacological class Secretolytic Expectorant, Mucolytic agent
General use Relief of productive cough and thick mucus
Origin Synthetic (derivative of Vasicine)

What Type of Medicine is Bromoxol?

Bromoxol is a medicinal product defined by its active therapeutic component, Bromhexine Hydrochloride, which is classified within therapeutic systems as a mucolytic. It functions as a secretolytic expectorant and mucolytic agent; this pharmacological role is clinically recognized for its efficacy in managing mucus disorders. Bromhexine is a chemically synthetic entity, having been derived through processes based on the structure of the naturally occurring alkaloid Vasicine. It is utilized as a single-ingredient product, which distinguishes it from combination cough remedies, providing a focused physiological action.


How Bromoxol Relates to Mucus and Cough

The primary general purpose of Bromoxol is to offer symptomatic relief from the difficulty associated with productive coughs when the mucus is thick and sticky, which is a typical use scenario during respiratory illness. It acts as a powerful mucolytic agent that actively works to reduce the viscosity of dense sputum by breaking down the fibers that give mucus its stickiness, thereby causing it to become more fluid. Review of the drug's action confirms its role in facilitating the clearance of secretions from the respiratory tract. Making the mucus substantially thinner and easier to mobilize helps to relieve chest congestion and support the body's natural airway clearance process.


Available Forms of Bromoxol

Bromoxol is typically offered in various forms suitable for oral administration, including a flavored syrup, liquid oral solutions, and compressed solid tablets. The availability of these different dosage forms allows for varied use depending on the patient group. While the most common and widely utilized forms are for the oral route, the medicinal entity is also manufactured as specialized injectable solutions for parenteral use, which are generally reserved for specific clinical and institutional settings requiring administration by injection.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Bromoxol?

Possible Side Effects and Safety Information: Bromoxol

The safety profile of Bromoxol (Bromhexine Hydrochloride) is officially documented according to System-Organ Class (SOC) groupings, detailing both expected and serious adverse reactions listed in regulatory product information. The majority of reported effects are generally mild and related to the Gastro-intestinal and Nervous System disorders.

Official Adverse Reaction Categories

Side effects that are classified as Uncommon or Occasionally include gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and upper abdominal pain. Neurological effects listed in this category may include headache and dizziness.

Serious Adverse Reactions

The most clinically significant safety information concerns rare, potentially life-threatening reactions that have been documented. These include Anaphylactic reaction and Anaphylactic shock (Immune system disorders). Regulatory documents also list Severe Cutaneous Adverse Reactions (SCARs), such as Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema Multiforme (EM), although reports of these conditions are considered Very Rare.

Regulatory Safety Considerations

Official labeling defines specific constraints for use in certain patient groups. The medicine is contraindicated in individuals with known hypersensitivity to Bromhexine. Caution is specified for patients with severe hepatic or renal impairment due to the potential for reduced drug clearance. Furthermore, use is generally not recommended during the first trimester of pregnancy or while breast-feeding.

Overdose and Emergency Response

The official regulatory profile for Bromoxol (Bromhexine Hydrochloride) overdose indicates that no specific unique overdose syndrome has been reported in humans. Symptoms observed following accidental overdose or medication error are instead consistent with an exaggeration of the medicine’s known side effects. These manifestations can include general disturbances such as nausea, vomiting, diarrhea, and upper abdominal pain, as well as headache, dizziness, and sweating. Furthermore, regulatory sources note that an overdose may cause an undesirable increase in the volume of bronchial secretions.

Due to the risk of severe outcomes, regulatory guidance mandates specific emergency actions. Immediate medical attention is required if severe manifestations occur, particularly signs of a serious allergic reaction (including swelling of the face or throat, wheezing, or sudden difficulties in breathing) or the appearance of a progressive skin rash (indicating severe cutaneous adverse reactions, SCARs). In these situations, the regulatory instruction is to stop treatment immediately and talk to a doctor or go to a hospital straight away, or to contact a Poisons Information Centre. Management procedures are defined by the lack of a specific antidote; official documentation states that treatment should consist of providing symptomatic and supportive treatment.

Therapeutic Uses of Bromoxol

What Bromoxol Treats: Main Uses and Benefits

Bromoxol is generally used for symptomatic management in patients experiencing acute discomfort, particularly when short-term symptomatic assistance is needed. The approach aligns with recognized clinical guidance and is relevant for easing certain distressing symptoms.


The medication is commonly used across conditions presenting with acute episodes or involving episodic manifestations. Bromoxol helps address symptom clusters that may become intense or disruptive, such as pronounced or distressing manifestations, and is considered relevant when symptoms that interfere with daily functioning create noticeable physiological strain. It is applied during phases when symptoms become more noticeable, offering supportive relief. Bromoxol may assist patients during difficult episodes by easing distress and contributing to improved comfort, helping to ease the overall symptom load.


Quick Fact: Relief for symptoms that create noticeable physiological strain


By assisting with symptom management, Bromoxol may assist with maintaining a sense of functional stability when symptoms become temporarily overwhelming.

Regulatory References

  1. European Medicines Agency (EMA) Guideline on Pain Treatment

Eligibility and Restrictions for Use

Who Can and Cannot Use Bromoxol?

This section details the official population eligibility and non-eligibility rules for Bromoxol (Bromhexine Hydrochloride) as defined in regulatory documents.

Eligibility Status Population/Condition Regulatory Classification
Contraindicated Hypersensitivity to bromhexine or excipients Absolute Prohibition
Children under 6 years of age Absolute Prohibition / Not Recommended
Allowed Adults and Adolescents (ge 12 years) General Use
Restricted Children 6 to 11 years of age Use only with advice of a doctor/pharmacist

Condition-Based Restrictions

Regulatory bodies advise caution for specific patient groups:

  • Severe Organ Impairment: Use with caution in patients with severe hepatic or renal impairment, as reduced clearance of the medicine or its metabolites may occur.
  • Gastrointestinal Status: Use with caution in patients with a history of gastric ulceration or existing peptic ulcer diseases, as mucolytics may potentially affect the gastric mucosal barrier.

Pregnancy and Lactation

  • Pregnancy: Not recommended during pregnancy, particularly in the first trimester. Avoidance is considered a precautionary measure due to limited available human data.
  • Lactation: Not recommended for use by breastfeeding mothers. It is not established whether the substance is excreted into human milk or has a harmful effect on the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation indicates that Bromoxol (Bromhexine Hydrochloride) has a low potential for clinically relevant unfavorable drug interactions. However, official drug labels document specific interaction patterns related to pharmacodynamic conflicts and effects on drug exposure.

Documented Interaction Patterns

Official prescribing information formally advises against combining Bromoxol with two specific substance categories, classified as pharmacodynamic conflicts due to their opposing actions:

  • Antitussives (Cough Suppressants): Combination is advised against as these agents suppress the cough reflex, which is necessary to clear the liquefied respiratory secretions facilitated by Bromoxol.
  • Secretion-Drying Medications: Co-administration is advised against because these drugs counteract Bromoxol's primary function of increasing and thinning respiratory secretions.

Bromoxol also exhibits an exposure-modifying effect when co-administered with certain antibiotics, resulting in increased concentrations of the antibiotic in sputum and bronchopulmonary secretions. This has been specifically documented for Amoxycillin, Erythromycin, and Oxytetracycline.

Population-Dependent Considerations

Official labels note that the elimination and clearance of Bromoxol and its metabolites may be decreased in patients with severe hepatic disease (severe liver impairment) or renal insufficiency (severe kidney failure), which may alter drug exposure in these populations.

Mechanism of Action

How Bromoxol Works

The mechanism of Bromoxol (Bromhexine) involves targeted pharmacodynamic actions that restructure the physical properties of respiratory secretions and enhance their transport. The primary mechanism is a secretolytic and mucolytic dual action on the composition and transport of tracheobronchial secretions.

Molecular Hydrolysis and Secretolytic Action

The Bromhexine molecule activates lysosomal enzymes within bronchial secretory cells, initiating the hydrolysis (breakdown) of long-chain acid mucopolysaccharide fibers. Simultaneously, it stimulates serous cells to increase their output of a watery, low-viscosity fluid.

Enhancement of Mucociliary Clearance

By reducing the viscosity of the secretions and increasing the fluid volume, Bromhexine enhances the efficiency of the cilia lining the tracheobronchial tree. This enhances the airway clearance pathway, facilitating the mobilization and clearance of secretions. The full physiological effect exhibits a time lag of two to three days, required for the drug to affect the formative stages of mucus.

Dosage and Administration Information

How Bromoxol Is Used: Official Administration Guidelines

Bromoxol (Bromhexine Hydrochloride) is administered according to specific patterns detailed in product information. Its primary route is oral, available as tablets (typically 8 mg strength) and liquid formulations, though it is also used for inhalation via nebuliser in some regions.


Dosing Schedule and Frequency

For adults and children over 12 years, the standardized regimen is typically 8 mg taken three times daily (t.i.d.). In the initial phase of treatment, the dose may be increased up to 16 mg three times daily for a maximum duration of seven consecutive days. Use beyond seven days requires professional guidance.


Administration Context and Adjustments

Bromoxol can be taken with or without food. For liquid formulations, precise measurement using the calibrated device provided with the product is required to ensure accurate dosing. The medicine is subject to population-specific adjustments; for individuals with severe renal or hepatic impairment, the recommended approach is administering a reduced dose or using longer dosing intervals due to the potential for metabolite accumulation.


Administration Condition Official Instruction
Missed Dose If a dose is missed and the next scheduled dose is imminent, the missed dose is to be skipped; a double dose must not be taken.
Inhalation Preparation The inhalation solution must be diluted with saline and administered exclusively via a nebulizer.
Pediatric Use Doses are scaled by age and weight, with restrictions on use in the youngest age groups depending on the regional label.

Recent Clinical Evidence

Evidence for Use in Mucus Clearance

The longest-standing research on Bromoxol was studied for mucus clearance in patients with respiratory conditions like chronic bronchitis. These studies, which include Controlled Clinical Trials, primarily monitored objective outcomes related to physical discomfort arising from mucus obstruction. Researchers examined changes in sputum quantity. Findings describe patterns observed in relation to sputum characteristics during the study period.

However, much of this foundational evidence was developed in an earlier era, and the quality may vary across studies. This has led to some mixed findings when the data is re-examined using contemporary analytical methods.


Evidence from Investigational Trials in Viral Pneumonia

A distinct and newer set of research has evaluated Bromoxol in the context of recent viral respiratory disease. These trials, primarily Randomized Controlled Trials (RCTs) and meta-analyses, explored a range of major clinical outcomes, including mortality and requirements for mechanical ventilation.

Findings across these studies were mixed, and pooled analyses have indicated that the statistical certainty for major endpoints remains low. This area is characterized by data that are still emerging, and the overall certainty remains low due to the variable nature of the reported outcomes.


⏱️ Research on Long-Term Outcomes and Follow-up Duration

The available evidence largely focuses on research exploring short-term symptom changes and acute episodes. For both the traditional use in mucus clearance and the investigational research, follow-up durations were limited, often spanning only a few weeks to one month. While studies monitor the initial response, long-term effects are not fully established, and there is limited information for long-term outcomes or the durability of any observed response.


‍‍ Evidence in Specific Patient Populations

Research was studied for a range of patient populations. For mucus clearance, trials have examined outcomes in adults with chronic respiratory conditions, and studies have also explored data related to children. Investigational trials primarily evaluated a population of adults who were observed in hospital settings. Data for specific subgroups, such as pregnant individuals or those with certain comorbidities, remain insufficient to draw broad conclusions.


Evidence Gaps and Areas of Uncertainty

For its use in mucus clearance, the evidence quality varies across studies, and many foundational documents used methodological approaches that are not common practice today. For the investigational use in viral pneumonia, the primary limitation is the conflicting nature of the results. Researchers state that the data are still emerging and that further high-quality research is necessary before any conclusions can be drawn. This research provides context but not individual predictions.

Key Studies & References

  1. Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial (MDPI)

Frequently Asked Questions (FAQ)

Common questions about Bromoxol (FAQ)


Q: Does Bromoxol interact with birth control pills?

A: Official drug documentation does not typically list hormonal contraceptives, such as birth control pills, as substances that cause a known, clinically relevant unfavorable interaction with Bromoxol. However, patient information suggests discussing all medicines being used with a healthcare professional, as they can check for specific product conflicts.


Q: Why is Bromoxol sometimes prescribed for conditions other than its main use?

A: Official documents describe that Bromoxol has been evaluated in investigational clinical trials for conditions other than its main use for mucus clearance, such as in recent viral respiratory disease. It is important to know the difference between the drug’s established, regulatory-approved use and its evaluation in research settings, where the data are still emerging and findings have been mixed.


Q: Does Bromoxol interact with supplements or vitamins?

A: Regulatory documents list specific interaction warnings related to other types of medicines (like cough suppressants and certain antibiotics). They do not generally provide a full review of non-medicinal supplements or vitamins. Discussing the use of all products, including supplements and vitamins, with a healthcare professional can provide specific guidance.


Q: Does alcohol change the way Bromoxol works?

A: Official product information commonly addresses the use of alcohol with medications. Regulatory labels may contain cautionary statements or advisories regarding the use of alcohol alongside Bromoxol. This is often because alcohol can potentially increase the occurrence of certain side effects, such as dizziness, which is listed as an occasional effect of Bromoxol.


Q: Can Bromoxol be crushed or split?

A: Official administration instructions detail how the liquid form should be measured and that tablets should be taken. They do not contain instructions that specifically allow tablets to be crushed or split. When a tablet form is not scored or when specific modification instructions are absent, official guidance suggests that tablets should be taken whole as manufactured.


Q: What are the typical expected outcomes described for people taking Bromoxol?

A: Official information indicates that Bromoxol is designed to facilitate the clearance of secretions from the respiratory tract. Research evidence focuses on outcomes related to the relief of physical discomfort caused by mucus obstruction and observed changes in sputum characteristics, making the mucus substantially thinner and easier to mobilize.


Q: Is the effectiveness of Bromoxol proven by high-quality evidence?

A: The drug is officially recognized for its mucolytic efficacy in product definitions. However, official reviews indicate that the quality of foundational research for its traditional use varies across studies. For newer investigational uses, data are still emerging and the certainty for major outcomes remains low. Overall, the evidence base is described as containing data of varying quality.


Q: Does Bromoxol cause weight gain or loss?

A: Official safety documents list common and uncommon side effects according to system-organ classes. Changes in body weight, whether gain or loss, are not generally listed among the frequent or occasional side effects reported in the official product information for Bromoxol.


Q: Does Bromoxol affect sleep patterns?

A: Regulatory documents list nervous system side effects such as headache and dizziness as effects that occur occasionally. They do not generally list specific disturbances to sleep patterns, like insomnia or excessive sleepiness, among the more common or notable side effects documented for Bromoxol.


Q: Are there any food restrictions while taking Bromoxol?

A: Official instructions state that Bromoxol can be taken with or without food. Regulatory information does not typically list specific dietary restrictions or food avoidance requirements for this medication.


Q: Does Bromoxol affect blood pressure readings?

A: Regulatory safety information does not commonly list high or low blood pressure as a frequent or occasional side effect associated with Bromoxol in its official adverse reaction categories. Concerns about blood pressure can be reviewed with a healthcare professional.


Q: Is there a generic version of Bromoxol available?

A: Bromoxol is the brand name for the active ingredient, Bromhexine Hydrochloride. As the active substance, Bromhexine is widely available worldwide in product forms authorized under various brand names and generic labels, depending on the region and the specific regulatory market.


Q: Is it possible to develop a dependency on Bromoxol?

A: Bromoxol is not classified as a controlled substance in major regulatory markets. Official product information and regulatory documents do not list the risk of dependence or substance abuse as a noted warning or precaution for its use.


Q: Is Bromoxol safe for teenagers?

A: Official eligibility rules classify adolescents, defined as individuals age 12 years and older, into the general use population for Bromoxol. Specific restrictions apply to younger children, requiring use to be scaled by age and weight.


Q: Does Bromoxol have any known drug-herb interactions?

A: Official labels specifically advise against combining Bromoxol with antitussives and secretion-drying medications. Regulatory labels do not typically provide an exhaustive list of interactions with herbal products. Patients typically discuss the use of any herbs with a healthcare professional.


Q: Is Bromoxol a short-term or long-term medication?

A: Bromoxol is typically described in official documents as being prescribed for short-term use, particularly to manage acute episodes involving thick mucus. The high-dose regimen is officially restricted to a maximum of seven consecutive days, and use beyond that period is generally recommended to be monitored by a professional.


Q: Can people with diabetes use Bromoxol?

A: Regulatory documents do not commonly list diabetes as a contraindication or a condition requiring special dosage precautions for Bromoxol. Specific precautions are usually reserved for severe hepatic or renal impairment. The use of this drug by patients with chronic conditions is commonly reviewed by a healthcare professional.


Q: Does Bromoxol interact with caffeine?

A: Regulatory documents do not generally list caffeine as a specific substance that causes a known, clinically relevant unfavorable interaction with Bromoxol.


Q: Does Bromoxol make people sensitive to sunlight?

A: Official regulatory documents list severe cutaneous adverse reactions as very rare. Photosensitivity, or increased sensitivity to sunlight, is not typically listed among the common or uncommon side effects of Bromoxol.


Q: Is there an official patient leaflet for Bromoxol available online?

A: Yes, official patient information leaflets (PILs), along with other equivalent documents like FDA DailyMed labels, are published by regulatory agencies. These are generally available to the public online through the websites of the national regulatory bodies, such as the EMA or FDA.


Q: How is Bromoxol's safety monitored after it is approved?

A: The safety of Bromoxol is continuously monitored after approval through a mandatory regulatory process called pharmacovigilance. This involves collecting, assessing, and analyzing reports of suspected adverse reactions that are submitted by patients and healthcare professionals to the regulatory agencies.


Q: Why is Bromoxol considered a prescription-only medicine?

A: Bromoxol is typically classified as a prescription-only medicine because its proper use requires professional guidance. This is necessary to ensure correct diagnosis, appropriate dosing adjustments for certain patient groups (like those with organ impairment), and monitoring for rare but severe adverse reactions.


Q: What does official guidance say about stopping Bromoxol suddenly?

A: Official prescribing information generally focuses on duration of use and does not commonly list specific risks or withdrawal symptoms associated with suddenly stopping Bromoxol. The discontinuation plan is typically determined by the prescribing healthcare professional.


Q: Can Bromoxol affect driving or operating machinery?

A: Official documentation advises caution regarding activities that require full attention, such as driving or operating machinery. This warning is included due to the occasional potential for side effects like headache or dizziness.


Q: Is a metallic taste in the mouth a side effect of Bromoxol?

A: Regulatory documents list gastrointestinal disturbances such as nausea and upper abdominal pain. A metallic taste is not generally listed among the common or uncommon side effects in the official product information for Bromoxol.

How should Bromoxol be stored and disposed of?

How to Store and Dispose of Bromoxol

Official regulatory documents prescribe specific storage and disposal rules for Bromoxol (Bromhexine Hydrochloride) to ensure stability and public safety.

Storage Requirements

The product must be stored at a temperature below 30 C and protected from light. The container must be kept tightly closed to prevent moisture exposure. For the liquid form, the shelf-life is typically limited to one month after first opening. Bromoxol must always be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired medicine should be returned using an authorized drug take-back program. If this is unavailable, the medicine must be rendered undesirable and mixed with household trash, following official guidelines. Do not flush Bromoxol down the toilet or release it into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromoxol found in:

A-Z Index: